UBS Group Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price

Key Points

• UBS raised its price target on CVS to $100 (from $97) and maintained a "buy" rating, implying roughly a 14.5% upside from the prior close.
• CVS delivered a strong Q1 beat and raised guidance—EPS $2.57 vs. $2.21 expected and revenue $100.43B vs. $94.99B—leading to multiple analyst upgrades and a consensus price target near $95.88.
• Valuation and PBM risk are potential headwinds: the stock trades at a high P/E (~63x) and some analysts caution that insurance-margin tailwinds in the PBM business may not be durable, which could limit long‑term upside.

CVS Health (NYSE:CVS - Get Free Report) had its target price upped by analysts at UBS Group from $97.00 to $100.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the pharmacy operator's stock. UBS Group's target price would indicate a potential upside of 14.50% from the stock's previous close.

Other analysts have also issued reports about the company. Leerink Partners reissued an "outperform" rating and set a $98.00 price objective on shares of CVS Health in a report on Thursday, March 5th. The Goldman Sachs Group boosted their price objective on CVS Health from $95.00 to $97.00 and gave the stock a "buy" rating in a report on Thursday, February 12th. HSBC boosted their price objective on CVS Health from $83.00 to $85.00 and gave the stock a "hold" rating in a report on Tuesday. Barclays boosted their price objective on CVS Health from $93.00 to $101.00 and gave the stock an "overweight" rating in a report on Thursday. Finally, TD Cowen reissued a "buy" rating on shares of CVS Health in a report on Friday, March 13th. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, CVS Health has a consensus rating of "Moderate Buy" and a consensus price target of $95.88.

CVS Health Stock Up 0.5%

CVS Health stock traded up $0.48 during midday trading on Thursday, reaching $87.34. The stock had a trading volume of 9,387,114 shares, compared to its average volume of 8,529,852. CVS Health has a 12 month low of $58.35 and a 12 month high of $88.63. The company has a market capitalization of $111.93 billion, a P/E ratio of 63.29, a PEG ratio of 0.84 and a beta of 0.60. The company has a fifty day moving average price of $76.60 and a two-hundred day moving average price of $78.00. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts' consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The business had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same period in the previous year, the company posted $2.25 EPS. The firm's revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities analysts expect that CVS Health will post 7.14 EPS for the current fiscal year.

Hedge Funds Weigh In On CVS Health

Several institutional investors have recently bought and sold shares of the company. Alteri Wealth LLC lifted its stake in CVS Health by 3.2% in the third quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator's stock valued at $316,000 after purchasing an additional 131 shares during the last quarter. TOWER TRUST & INVESTMENT Co lifted its stake in CVS Health by 0.8% in the fourth quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator's stock valued at $1,247,000 after purchasing an additional 132 shares during the last quarter. Holistic Financial Partners lifted its stake in CVS Health by 4.1% in the third quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator's stock valued at $256,000 after purchasing an additional 133 shares during the last quarter. CYBER HORNET ETFs LLC lifted its stake in CVS Health by 4.1% in the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator's stock valued at $259,000 after purchasing an additional 134 shares during the last quarter. Finally, LS Investment Advisors LLC lifted its stake in CVS Health by 3.9% in the fourth quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator's stock valued at $284,000 after purchasing an additional 135 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q1 beat and guidance raise — CVS reported Q1 adjusted EPS and revenue well above Street estimates, cited reserve benefits and better-than-expected Aetna medical margins, and raised FY‑2026 adjusted EPS guidance. This is the primary catalyst for the rally. CVS Raises 2026 Outlook As Shares Jump 9.8%
• Positive Sentiment: Analyst upgrades and higher price targets — Multiple firms (Truist, DA Davidson, Deutsche Bank and others) bumped targets and kept/added buy ratings after the print, amplifying demand from institutional investors. Truist price target raise DA Davidson raises target Deutsche Bank adjusts target
• Positive Sentiment: Strong cash/profit snapshot — Reports highlight a $2.9B Q1 profit and expanding margins tied to insurance performance, supporting the company's higher cash-flow guidance. CVS Health reports $2.9B in Q1 profit
• Neutral Sentiment: Biosimilars, AI and community programs — CVS is expanding biosimilar formulary adoption and launching AI/local initiatives to lower costs and improve access; these are longer‑term drivers rather than immediate earnings catalysts. CVS Health Bets On Biosimilars And AI To Support Affordable Care
• Neutral Sentiment: Economic impact report/PR — A company release on CVS’s large economic footprint is positive for reputation but unlikely to move near-term fundamentals. CVS Health's Annual Impact in Connecticut
• Negative Sentiment: Valuation and structural PBM risk — Analysis warns that temporary insurance-margin tailwinds may mask longer-term structural margin pressure in the PBM business, implying a potential valuation ceiling if durable margin improvement stalls. How CVS Health's Transformation Is Facing A Hard Valuation Floor

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.